Literature DB >> 20516140

Pharmacological characterization of the allosteric modulator desformylflustrabromine and its interaction with alpha4beta2 neuronal nicotinic acetylcholine receptor orthosteric ligands.

Maegan M Weltzin1, Marvin K Schulte.   

Abstract

Neuronal nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop superfamily of ligand-gated ion channels. nAChRs are involved in modulating nicotinic-based signal transmission in the central nervous system and are implicated in a range of disorders. Desformylflustrabromine (dFBr) is a positive allosteric modulator that potentiates alpha4beta2 nAChRs. It has been reported that dFBr is selective for the alpha4beta2 receptor relative to other common nAChR subtypes (Neurosci Lett 373:144-149, 2005). Coapplication of dFBr with acetylcholine (ACh) produces a bell-shaped dose-response curve with a peak potentiation of more than 265% (Bioorg Med Chem Lett 17:4855-4860, 2007) at dFBr concentrations <10 microM and inhibition of responses at concentrations >10 microM. The potentiation and inhibition components of dFBr-modulated responses were examined by using two-electrode voltage clamp and human alpha4beta2 nAChRs expressed in Xenopus laevis oocytes. Currents to both partial and full agonists were potentiated by dFBr. Responses to low-efficacy agonists were potentiated significantly more than responses to high-efficacy agonists. Antagonist pIC(50) values were unaffected by coapplication of dFBr. In addition to its potentiating effects, dFBr was able to induce current spikes when applied to desensitized receptors, suggestive of a shift in equilibrium from the desensitized to open conformation. In contrast to potentiation, inhibition of ACh responses by dFBr depends on membrane potential and is probably the result of open-channel block by dFBr and ACh. Our data indicate distinct mechanisms for the potentiation and inhibition components of dFBr action. dFBr could prove useful for therapeutic enhancement of responses at alpha4beta2-containing synapses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20516140      PMCID: PMC2939658          DOI: 10.1124/jpet.110.167684

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

1.  Structural basis for partial agonist action at ionotropic glutamate receptors.

Authors:  Rongsheng Jin; Tue G Banke; Mark L Mayer; Stephen F Traynelis; Eric Gouaux
Journal:  Nat Neurosci       Date:  2003-08       Impact factor: 24.884

2.  Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor.

Authors:  R M Krause; B Buisson; S Bertrand; P J Corringer; J L Galzi; J P Changeux; D Bertrand
Journal:  Mol Pharmacol       Date:  1998-02       Impact factor: 4.436

3.  Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits.

Authors:  S C Harvey; F N Maddox; C W Luetje
Journal:  J Neurochem       Date:  1996-11       Impact factor: 5.372

4.  A vertical flow chamber for Xenopus oocyte electrophysiology and automated drug screening.

Authors:  P R Joshi; A Suryanarayanan; M K Schulte
Journal:  J Neurosci Methods       Date:  2004-01-15       Impact factor: 2.390

5.  Tuning activation of the AMPA-sensitive GluR2 ion channel by genetic adjustment of agonist-induced conformational changes.

Authors:  Neali Armstrong; Mark Mayer; Eric Gouaux
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-02       Impact factor: 11.205

Review 6.  Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists.

Authors:  Joseph I Friedman
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

7.  Molecular analysis of nicotinic receptor expression in autism.

Authors:  C M Martin-Ruiz; M Lee; R H Perry; M Baumann; J A Court; E K Perry
Journal:  Brain Res Mol Brain Res       Date:  2004-04-07

8.  Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures.

Authors:  Patrick H N Celie; Sarah E van Rossum-Fikkert; Willem J van Dijk; Katjusa Brejc; August B Smit; Titia K Sixma
Journal:  Neuron       Date:  2004-03-25       Impact factor: 17.173

9.  Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core.

Authors:  Hiroyasu Furukawa; Eric Gouaux
Journal:  EMBO J       Date:  2003-06-16       Impact factor: 11.598

10.  Comparison of taurine- and glycine-induced conformational changes in the M2-M3 domain of the glycine receptor.

Authors:  Nian-Lin R Han; John D Clements; Joseph W Lynch
Journal:  J Biol Chem       Date:  2004-02-23       Impact factor: 5.157

View more
  27 in total

1.  Allosteric modulation of alpha4beta2 nicotinic acetylcholine receptors by HEPES.

Authors:  Maegan M Weltzin; Yanzhou Huang; Marvin K Schulte
Journal:  Eur J Pharmacol       Date:  2012-06-23       Impact factor: 4.432

2.  Structure-activity relationship studies of sulfonylpiperazine analogues as novel negative allosteric modulators of human neuronal nicotinic receptors.

Authors:  Brandon J Henderson; Daniel J Carper; Tatiana F González-Cestari; Bitna Yi; Kiran Mahasenan; Ryan E Pavlovicz; Martin L Dalefield; Robert S Coleman; Chenglong Li; Dennis B McKay
Journal:  J Med Chem       Date:  2011-11-18       Impact factor: 7.446

Review 3.  Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors.

Authors:  Jingyi Wang; Jon Lindstrom
Journal:  Br J Pharmacol       Date:  2017-03-20       Impact factor: 8.739

4.  NMR structures of the transmembrane domains of the α4β2 nAChR.

Authors:  Vasyl Bondarenko; David Mowrey; Tommy Tillman; Tanxing Cui; Lu Tian Liu; Yan Xu; Pei Tang
Journal:  Biochim Biophys Acta       Date:  2012-02-14

5.  Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptors.

Authors:  M Grupe; A A Jensen; P K Ahring; J K Christensen; M Grunnet
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

Review 6.  Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Biochem Pharmacol       Date:  2011-05-14       Impact factor: 5.858

7.  Effects of nicotine in combination with drugs described as positive allosteric nicotinic acetylcholine receptor modulators in vitro: discriminative stimulus and hypothermic effects in mice.

Authors:  Megan J Moerke; Fernando B de Moura; Wouter Koek; Lance R McMahon
Journal:  Eur J Pharmacol       Date:  2016-05-27       Impact factor: 4.432

8.  A Novel α2/α4 Subtype-selective Positive Allosteric Modulator of Nicotinic Acetylcholine Receptors Acting from the C-tail of an α Subunit.

Authors:  Jingyi Wang; Alexander Kuryatov; Zhuang Jin; Jack Norleans; Theodore M Kamenecka; Paul J Kenny; Jon Lindstrom
Journal:  J Biol Chem       Date:  2015-10-02       Impact factor: 5.157

Review 9.  Recent progress in neuroactive marine natural products.

Authors:  Ryuichi Sakai; Geoffrey T Swanson
Journal:  Nat Prod Rep       Date:  2014-01-17       Impact factor: 13.423

10.  Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration.

Authors:  Xiu Liu
Journal:  Psychopharmacology (Berl)       Date:  2013-05-28       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.